Harrow (HROW) Stock Forecast: StockMap's 2-Week Call
HROW stock forecast: StockMap's model leans Underperform on Harrow for the two weeks after the Nov 13 close, toward HROW trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Too few two-week windows graded to judge yet.
Harrow last closed at $30.12, +6.43% on the session.
Against the IVW growth benchmark the position is +7.34% over the forecast window.
Harrow's market cap is $1.13B as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -45 (too close to call).
Where HROW sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
15 daily calls for HROW so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Harrow in the 12th percentile on return on equity, where 100 is best.
Harrow is classified under Health Care / Pharmaceuticals.
StockMap tracks Harrow as the 64th largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 73 Moderate Underperform, 49 Neutral and 30 Strong Underperform.
On that composite Harrow ranks 111th of 152 in the group, against a group median of -0.33.